-Reuters
Analysts Stay Bullish On Arcellx’s CART-ddBCMA’s Long-term Therapeutic Potential
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program.
Related Posts
Biophytis Plans To File IND With FDA For Phase 2 OBA Clinical Study In Obesity, Backed By New Scientific Advisory Board
IND to be filed with the FDA in the coming weeks
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS), ("Biophytis" or the "Company"), a
No More Crypto Roller Coasters: Hong Kong’s First Digital’s Stablecoin Promises Smooth Ride
First Digital, a Hong Kong-based trust company and authorized custodian, announced the introduction of its new U.S. dollar-pegged stablecoin, which will be governed by regulations in Asia.
Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs; Says 201 Trial Is ~75% Enrolled
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"),